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Abstract
Background: Carbonic anhydrase IX is a member of α-carbonic anhydrases that is preferentially expressed in solid
tumors. It enables bicarbonate transport across the plasma membrane, neutralizing intracellular pH and conferring
to cancer cells a survival advantage in hypoxic/acidic microenvironments. Overexpression of carbonic anhydrase IX
in cancer tissues is regulated by hypoxia inducible factor 1α −mediated transcription and the enzyme is considered
a marker of tumor hypoxia and poor outcome. The role of carbonic anhydrase IX in prostate cancer has not been
fully clarified and controversy has arisen on whether this enzyme is overexpressed in hypoxic prostate cancer
tissues.
Methods: We analyzed the expression of carbonic anhydrase IX and hypoxia inducible factor 1α in two prostate
cancer cell lines, LNCaP and PC-3, and in 110 cancer biopsies, by western blotting and immunocyto/histochemistry.
Results: In LNCaP and PC-3 cells, carbonic anhydrase IX was mostly cytoplasmic/nuclear, with very limited
membrane localization. Nuclear staining became stronger under hypoxia. When we analyzed carbonic anhydrase IX
expression in human prostate cancer biopsies, we found that protein staining positively correlated with hypoxia
inducible factor 1α and with Gleason pattern and score, as well as with the novel grading system proposed by the
International Society of Urological Pathology for prostate cancer. Once more, carbonic anhydrase IX was mainly
cytoplasmic in low grade carcinomas, whereas in high grade tumors was strongly expressed in the nucleus of the
neoplastic cell. An association between carbonic anhydrase IX expression level and the main clinic-pathological
features involved in prostate cancer aggressiveness was identified.
Conclusions: There was a statistically significant association between carbonic anhydrase IX and hypoxia inducible
factor 1α in prostate cancer tissues, that identifies the enzyme as a reliable marker of tumor hypoxia. In addition,
carbonic anhydrase IX expression positively correlated with prostate cancer grading and staging, and with outcome,
suggesting that the protein may be an independent prognosticator for the disease. The nuclear translocation of the
enzyme in hypoxic cancer cells may epitomize a biological switch of the tumor towards a less favorable phenotype.
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Background
Carbonic anhydrase (CA) IX is a membrane-associated
glycoprotein, belonging to the family of α-carbonic anhy-
drases that catalyze the reversible hydration of carbon diox-
ide to bicarbonate ions and protons [1]. Sixteen isoforms of
CA have been identified in humans: five are cytosolic (CA
I, II, III, VII and XIII), five are membrane-bound (CA IV,
IX, XII, XIV and XV), two reside in the mitochondria (CA
VA and VB) and one is secreted in milk and saliva (CA VI).
Moreover, three non-catalytic isoforms have been described
and designated CA-related proteins (CARP VIII, X and XI)
[2]. The catalytic-competent isoforms perform many bio-
logical functions, involving pH regulation and ion transport
in many organs [3]. Of all isoforms, CA IX is preferentially
expressed in solid tumors and its presence in normal tissues
is limited to the gastrointestinal tract where the enzyme is
implicated in cell proliferation and differentiation [4, 5].
CA IX consists of a short intracellular tail, a transmem-
brane region, a large extracellular domain (ectodomain)
which retains the catalytic activity and displays a unique
proteoglycan-like domain which seems to favor cell-
adhesion processes. The protein also comprises a signal
peptide [6].
The overexpression of CA IX in cancer tissues is strongly
regulated by hypoxia, through the hypoxia-inducible factor
(HIF)-1 mediated transcription [7, 8]. Indeed, the ability of
the enzyme to neutralize intracellular pH, by facilitating bi-
carbonate transport across the plasma membrane, confers
to cancer cells a survival advantage when they are exposed
to hypoxic and acidic microenvironments [9]. Moreover, by
intensifying the extracellular acidosis, CA IX facilitates the
activation of proteases that degrade the extracellular matrix,
stimulating migration and invasion of the surrounding tis-
sues [10].
In addition to the hypoxia-induced modulation of gene
transcription, the level of CA IX detected on cell surface
is dependent on two additional mechanisms of regulation:
endocytosis and ectodomain (ECD) shedding [3]. Endo-
cytosis is also positively controlled by hypoxia [11] while
ECD shedding seems to be supported by at least two dis-
tinct metalloproteases [12]. Whether ECD released into
the extracellular space is inactive or is biologically active is
still unknown.
Hypoxia is a common feature of prostate cancer (PC)
and foreshadows a poor prognosis [13]. The first indica-
tion that carbonic anhydrases may be relevant for PC cell
survival derives from the work of Supuran et al. that de-
scribed the antitumor effect of CA inhibitors on several
cancer cell lines, including prostate cancer [14, 15]. Re-
cently, Fiaschi et al. clearly demonstrated the presence of
CA IX in three different PC cell lines, PC-3, Du145 and
LNCaP [10]. In human tissues, a study conducted in 9
men undergoing needle oxygen measurements and biopsy
of tumor bearing prostate glands, demonstrated CA IX
positivity in areas of hypoxia [16]. On the contrary, in an
immunohistochemistry study of more than 150 PC biop-
sies, Smyth et al. reported only an occasional positivity to
CA IX immunostaining, even in the presence of hypoxic
areas within the tumor [17]. The authors concluded that
CA IX should not be considered a suitable marker of hyp-
oxia in PC.
We have recently reported that hypoxia induces up-
regulation of Notch 3 receptor and that Notch 3 expres-
sion correlates with the hypoxia-dependent markers, HIF-
1α and CA IX, in human PC biopsies [18, 19]. We now
analyze the hypoxia-induced response of CA IX in PC cell
lines and extend the study of its expression to a larger




For immunohistochemical analyses, 140 core needle bi-
opsy specimens from 110 prostate cancer patients and 30
cancer-free patients were collected between January 2012
and September 2013, at the Urological Division of Siena
University Hospital (Siena, Italy). Mean age at the time of
biopsy was 70 years (range: 58 to 86 years); only patients
without previous hormonal or radiation therapy were in-
cluded in the study. Since the corresponding radical pros-
tatectomy was available for each patient, the following
clinic-pathological parameters were recorded: Gleason
score and 2015 International Society of Urological Path-
ology (ISUP) grading, surgical margins infiltration, extra-
prostatic extension, seminal vesicles invasion, lymph node
metastasis, TNM staging (based on the AJCC Cancer Sta-
ging Manual, seventh edition, 2010, Springer New York,
inc) and recurrence.
Antibodies and chemicals
Anti-GAPDH antibody was obtained from Cell Signaling
Technology (EuroClone, Milan, Italy); anti-HIF-1α anti-
body was obtained from Novus Biologicals (DBA, Italy)
and anti-CA-IX (M75) antibody from Bioscience (Slovakia
S.R.O.) [20]. Horseradish peroxidase (HRP)-conjugated
secondary antibodies were purchased from Pierce Biotech-
nology Inc. (EuroClone, Milan, Italy). All other reagents
were obtained from Sigma unless otherwise stated.
Cell cultures
The androgen-dependent human prostate cancer cell line,
LNCaP, and the androgen-independent cell line, PC-3, were
obtained from ATCC (LGC Standards S.r.l., Italy), main-
tained in liquid nitrogen and used within few weeks after
thawing and plating. Cells were grown in RPMI-1640
(EuroClone) (LNCaP) and DMEM (PC-3), supplemented
with 10 % (vol/vol) fetal bovine serum (FBS) (EuroClone),
L-glutamine (EuroClone) and 1 % (vol/vol) antibiotic/
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antimycotic solution (Gibco, Invitrogen S.r.l.). Hypoxia was
achieved by maintaining the cells at 2 % oxygen, for 24 h,
in a CO2 incubator (Forma Series II, Thermo Scientific)
with oxygen sensor control, and CO2 and N2 gas regulators
[18].
Western blotting
For detection of CA IX, cells were lysed in cold buffer
(10 mM TrisHCl pH 7.4, 25 mM MgCl2, 1 % Triton X-
100, 1 mM dithiothreitol, 0.1 mM phenylmethylsulfonyl
fluoride, 10 μg/ml leupeptin, 2 μg/ml aprotinin, 1 mM
Na3VO4) and resolved by 10 % SDS-PAGE. CA IX immu-
noreactive bands were visualized by chemioluminescence
(ECL) (GE Healthcare Italia, Euroclone, Milan, Italy).
GAPDH was used for normalization of protein loading.
Immunocytochemistry
Cells were grown under normoxia or hypoxia as previously
described [18]. Immunocytochemistry was performed using
the HRP multimer system (Ultra Vision Quanto Detector
System, Thermo Scientific, Bio-Optica, Milan, Italy) and
anti-CA-IX and anti-HIF-1α antibodies. 3,30-diaminobenzi-
dine (DAB; Quanto, Thermo Scientific) was used as
chromogen for the development of peroxidase activity
(Hydrogen Peroxide Block Kit, Thermo Scientific).
Histology and Immunohistochemistry
Core needle biopsy specimens were fixed in 10 % buffered
formalin and embedded in paraffin; 4 μm-thick sections
were cut from each block and stained with hematoxylin
and eosin. Tumor pattern and score was established ac-
cording to the modified Gleason grading system [21, 22] in
each core needle biopsy, by two expert pathologists (MTdV
and MRA) that reached a consensus in all cases. Tumors
were classified as Gleason score 6, 7 (3 + 4 and 4 + 3), 8, 9
and 10, and grouped according to the recently proposed
ISUP grading system for PC in grade 1 to 5 [23]. Staining
was performed on 4+ 0.5 μm-thick sections of each block
using the Ultravision Detection System Anti-Polyvalent
HRP (Ultra V Block) (LabVision, Fremont, CA, USA, Bio-
Optica). Slides were incubated with anti-CA-IX (dilution:
1:50) and anti-HIF-1α (dilution: 1:50) antibodies, using
DAB as chromogen. Sections were weakly counterstained
with Harris’ hematoxylin and examined under a light
microscope. Non-immune serum immunoglobulins were
used as negative controls. Clear cell renal cell carcinoma
was used as positive control for both antibodies.
Staining assessment
All samples were independently evaluated and scored by
two investigators (BJR and AG). CA IX and HIF-1α protein
expression was classified combining the percentage and the
intensity of positively stained cells [24]. The percentage was
scored as follows: 1 (<5 % positive cells), 2 (5–50 % positive
cell), and 3 (>50 % positive cells). The intensity of staining
was scored as follows: 1 (weak or not detectable staining), 2
(moderate staining) and 3 (strong staining). Three different
fields (at least 100 cells/field) were evaluated at x200 magni-
fication. The sum of the percentage score and the intensity
staining score was used to define CA IX and HIF-1α pro-
tein expression as low (0–2) or high (3–4). The agreement
between the two pathologists was about 90 %. Cases with
discrepancies were reviewed and discussed to reach 100 %
concordance. In Gleason score 7 and 9 samples, staining
assessment was performed separately in the two patterns
(i.e. 3 and 4 in Gleason score 7, and 4 and 5 in Gleason
score 9).
Statistical analysis
Statistical analysis was performed using a statistical soft-
ware package (SigmaPlot 12.0, Systat Software). The cor-
relation between CA IX and HIF-1α expression, and
Gleason and 2015 ISUP grading was evaluated by the
Spearman Rank Order Correlation Test. When comput-
able, the Fisher exact test was applied to contingency
tables to evaluate the association between the frequency
distribution of CA IX and each qualitative variable. We
alternatively used the classic Chi-square test. A p < 0.05
was considered statistically significant.
Results and discussion
Expression of CA IX is up-regulated by hypoxia and is
mainly nuclear in PC cells
Fiaschi et al. [10] have shown the expression of CA IX
in several PC cell lines. We tested whether its expression
was up-regulated by hypoxia in LNCaP and PC-3 cells.
Under normoxia, the enzyme was expressed very poorly
in LNCaP cells but was easily detected in PC-3 cells.
a
b
Fig. 1 Western blot analysis of CA IX in LNCaP and PC-3 cells, under
normoxia and hypoxia. Low protein expression is detected in LNCaP
(a) and PC-3 (b) cells under normoxia (N). Under hypoxia (H) the
staining becomes evident and is stronger in PC-3 than LNCaP cells.
GAPDH is used as control for protein loading
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Fig. 2 Immunocytochemical analysis of CA IX in LNCaP and PC-3 cells, under normoxia and hypoxia. Under normoxia, a negligible CA IX cytoplasmic
staining is detected in LNCaP (a) and PC-3 (b) cells, with few positive nuclei. In response to hypoxia, a strong positivity for CA IX appears in the cytoplasm
and in the nucleus of LNCaP (c) and PC-3 cells (d) (a-d, original magnification (O.M.): 400x)
Fig. 3 Immunocytochemical analysis of HIF-1α in LNCaP and PC-3 cells, under normoxia and hypoxia. No staining or mild cytoplasmic positivity
for HIF-1α is detected in LNCaP (a) and PC-3 (b) cells, under normoxia. Under hypoxia, cytoplasmic positivity becomes stronger, both in LNCaP
(c) and PC-3 cells (d). Nuclear translocation of the protein is also evident (c-d) (a-d, O.M.: 400x)
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Under hypoxia, CA IX expression was up-regulated in
both cell lines (Fig. 1). This is not surprising consid-
ering that CA IX is a well-known hypoxia-induced
gene [25, 26]. Remarkably, when the expression of
CA IX was analyzed by immunocytochemistry, a low
cytoplasmic staining was detected in scattered cells,
with some positive nuclei (Fig. 2a-b). In response to
hypoxia, the staining became stronger and the protein
was expressed mainly in the nucleus (Fig. 2c-d). The
intensity of the staining was higher in PC-3 cells,
both under normoxia and hypoxia (Fig. 2b-d). Positiv-
ity for HIF-1α confirmed the effectiveness of the hyp-
oxia protocol (Fig. 3).
Expression of CA IX and HIF-1α in PC biopsies correlates
with Gleason pattern and score
We analyzed 30 non neoplastic specimens (18 with atro-
phy and 12 with atrophy plus chronic inflammation) and
110 cancer biopsies, from high grade prostate intraepithe-
lial neoplasm (HGPIN) (N = 20), to Gleason score 6 (N =
20), Gleason score 7 (N = 20), Gleason score 8 (N = 30),
Gleason score 9 (N = 10), and Gleason score 10 (N = 10).
In HGPIN, a low cytoplasmic staining for CA IX and HIF-
1α was observed, with scattered positive nuclei (Fig. 4a-c).
CA IX and HIF-1α protein expression was lower in low
Gleason pattern (i.e. 3) (Fig. 4d-f) compared to high Glea-
son pattern (i.e. 4 and 5) (Fig. 4g-i and l-n, respectively). In
Gleason pattern 3, CA IX positivity was mainly cytoplas-
mic, whereas in Gleason pattern 4 and 5, the enzyme was
detected in the cytoplasm and in the nucleus of all neo-
plastic cells. In addition, CA IX and HIF-1α immunostain-
ing was significantly lower in Gleason score 6 than in
Gleason score 8 to 10. In Gleason score 7, an intra-
tumoral heterogeneity was observed, with a higher expres-
sion level of both proteins in Gleason pattern 4 than in
Gleason pattern 3. These findings were better exemplified
Fig. 4 Immunohistochemical analysis of CA IX and HIF-1α in HGPIN and Gleason pattern 3 to 5. Low cytoplasmic staining for CA IX and HIF-1α in
HGPIN (a-c); low-to-moderate cytoplasmic staining, with few positive nuclei, for CA IX and HIF-1α in Gleason pattern 3 (d-f); strong cytoplasmic
and nuclear expression of CA IX and HIF-1α in Gleason pattern 4 (g-i) and 5 (l-n) (a,d,g,l: hematoxylin and eosin (H&E); b,e,h,m: CA IX staining;
c,f,i,n: HIF 1α staining. O.M. 200x)
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by using the novel 2015 ISUP grading system for PC that
highlights how Gleason score 3 + 4 = 7 really is a different
form of histology compared to Geason score 4 + 3 = 7. We
found that 3 to 5 PC grade groups highly expressed CA IX
and HIF-1α in comparison to grade groups 1–2. The cor-
relation between the level of expression of CA IX and HIF-
1α, and Gleason (pattern and score) and ISUP grading was
statistically significant (p < 0.001) and is summarized in
Tables 1, 2, 3 and 4. No staining was detected in non-
neoplastic specimens for both antibodies, except for
8 samples with atrophy showing a low level of CA
IX expression (Fig. 5). Stromal and endothelial cells
intermingled with non-neoplastic glands demonstrated
significant CA IX positivity (see arrows). The intensity
of expression of CA IX directly correlated with
TNM stage (p < 0.001), surgical margins infiltration
(p < 0.001), extra-prostatic extension (p < 0.001), seminal
vesicle invasion (p < 0.001) and lymph node metastasis
(p < 0.001). Interestingly the patients with higher CA IX
expression recurred more frequently than those with
lower level. However, a longer follow-up is mandatory
to assess the real impact of the protein expression on
patients’ outcome.
CA IX is an attractive target for innovative anti-
cancer therapies due to its role in promoting survival of
cancer cells in inhospitable microenvironments. Since
the discovery of isoform IX [1], the primary scientific
interest has revolved around its membrane-bound en-
zymatic activity which regulates extra and intracellular
pH and sustains cancer cell migration, metastatization
and tumor progression [10]. Only in recent years, it
became apparent that CA IX likely plays additional
roles inside the cell. Those roles are recapped by the
presence of the protein in different sub-cellular com-
partments. A strong CA IX cytoplasmic staining was
detected in squamous cell head and neck cancers and
was related to poor response to chemotherapy [27, 28].
In non-small-cell lung cancer, perinuclear CA IX was
an independent poor prognostic marker [29]. In neuro-
blastoma, nuclear CA IX expression was significantly
higher in patients with adverse clinical and pathological
features [30]. In PC tissues, the unconventional location
of the protein is quite striking. In a limited series of hu-
man biopsies, we previously demonstrated that CA IX
is mainly cytoplasmic in low grade carcinomas, whereas
it is strongly expressed in the cytoplasm and in the nu-
cleus of high grade tumor cells [19]. We have now ex-
tended this observation to a larger series of human PC
biopsies, confirming our previous findings. Unlike
Smyth et al. that reported only an occasional CA IX
positivity in hypoxic areas [17], we found a statistically
significant association between CA IX and HIF-1α ex-
pression in PC that identifies the protein as a reliable
marker of tumor hypoxia.
Hypoxia orchestrates a composite intracellular re-
sponse in tumor cells. HIF-1α induces the expression
of several other factors, including VEGF, lysyl oxidase
(LOX) and CA IX, all potentially relevant in the con-
text of PC biology [31]. However, how the interaction
between these factors modulates the progression of
the tumor or what is the combination of markers that
better predicts an unfavorable outcome is still un-
determined [32]. Since CA IX represents a marker of
hypoxia and since hypoxia induces resistance to
Table 1 CA IX expression and Gleason score
Gleason score N High Low
6 20 5 15
7 20 12 8
8 30 27 3
9 10 9 1
10 10 10 0
N: number of cases
p < 0.001
Table 2 HIF-1α expression and Gleason score
Gleason score N High Low
6 20 3 17
7 20 11 9
8 30 25 5
9 10 9 1
10 10 9 1
N: number of cases
p < 0.001
Table 3 CA IX expression and 2015 ISUP grading system
ISUP grading N High Low
1 20 5 15
2 10 3 7
3 10 8 2
4 30 27 3
5 20 18 2
N: number of cases
p < 0.001
Table 4 HIF-1α expression and 2015 ISUP grading system
ISUP grading N High Low
1 20 3 17
2 10 2 8
3 10 9 1
4 30 25 5
5 20 18 2
N: number of cases
p < 0.001
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radiotherapy, it is reasonable that high level of the
protein may impact the response to therapy in
muscle-invasive PC.
We found a positive correlation between CA IX ex-
pression and the most relevant prognostic factors of
PC (Gleason score, ISUP 2015 grading system, TNM
stage). Indeed, the nuclear localization of the enzyme
may epitomize a biological switch that stirs the tumor
towards a worst outcome. The limited expression of
CA IX in LNCaP cells, compared to PC-3 cells, is in
line with the association of the enzyme with malig-
nancy. Fiaschi et al. demonstrated that CA IX is
expressed by prostate cancer-associated fibroblasts,
upon their activation by cancer-delivered soluble fac-
tors, and that the enzyme mediates the epithelial-
mesenchymal transition of cancer cells, with subse-
quent increased motility, survival and tumor stemness
[10]. These data further support a central role of CA
IX in PC progression. Further studies will be necessary
to elucidate whether CA IX represents an independent
poor prognostic marker in PC patients.
Recently, Buanne et al. [33] designed the “interac-
tomic” map of CA IX, demonstrating that the majority
of partners were proteins that belong to the nuclear
transport machinery. These data support the notion
that CA IX is able to transit through the nuclear com-
partment. They also found that hypoxia increases CA
IX nuclear accumulation [33]. The study also indicated
that the peptide detected in the nuclear/perinuclear re-
gion encompasses the extracellular, catalytic domain,
likely representing an endocytosed fraction of the full-
length transmembrane protein [33, 34]. Our data also
indicate that nuclear-bound CA IX encompasses the N-
terminal extracellular region, being detected by a monoclo-
nal antibody directed against the proteoglycan-like domain.
Whether nuclear-bound CA IX has a role in cellular signal-
ling and/or regulation of transcription is still unclear. How-
ever, it is interesting that a transcription factor with CA
activity has been identified in human tissues, suggesting
that CA IX may act as a transcription factor [35]. In any
case, the possibility that cytoplasmic/nuclear-localized CA
IX may have distinct biological functions than the
membrane-bound protein should be acknowledged.
Conclusion
CA IX is readily detected in PC tissues and correlates with
the expression of HIF-1α, defining the protein a suitable
marker of hypoxia in this tumor. Moreover, the expression
of CA IX correlates with Gleason grade and score, indicat-
ing that the enzyme may contribute to tumor progression.
Cytoplasmic/nuclear-bound CA IX may display previously
unrecognized, alternative biological functions that should
be defined further before the enzyme may be considered
as a target for novel anti-cancer therapies.
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